Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders

Drugs

Volumn 54, Issue 1, 1997, Pages 161-185

  Dunn, Christopher J ^a   Lea, Andrew P ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; BARBITURIC ACID DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARVEDILOL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FREE RADICAL; GUANETHIDINE; GUANFACINE; HYDROCHLOROTHIAZIDE; LIPID; METHYLDOPA; PHENOTHIAZINE; RESERPINE; TRICYCLIC ANTIDEPRESSANT AGENT; VASODILATOR AGENT;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ASTHENIA; BRADYCARDIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CELL DAMAGE; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DYSPNEA; ESSENTIAL HYPERTENSION; EXERCISE TOLERANCE; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE NECROSIS; HEART PROTECTION; HUMAN; LIPID BLOOD LEVEL; MALAISE; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; REVIEW; VASODILATATION; VERTIGO;

ANGINA; ANIMALIA;

EID: 0030843847     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754010-00015     Document Type: Review

References (179)

1. McTavish D, Campoli-Richards D, Sorkin EM, Carvedilol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993 Feb; 45: 232-58
2. 1-adrenoceptors. Chirality 1989; 1: 265-70
3. Feuerstein G, Yue T-L, Ruffolo JRR. Carvedilol update: a multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Drugs Today 1993 Sep; 29: 401-14
4. Yue TL, Lysko PG, Barone FC, et al. Carvedilol, a new antihypertensive drug with unique antioxidant activity: potential role in cerebroprotection. Ann NY Acad Sci 1994 Nov 17; 738: 230-42
5. Bristow MR, Larrabee P, Minobe W, et al. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992; 19 Suppl, 1: S68-80
6. Monopoli A, Forlani A, Bevilacqua M, et al. Interaction of selected vasodilating β-blockers with adrenergic receptors in human cardiovascular tissues. J Cardiovasc Pharmacol 1989 Jul; 14: 114-20
7. Hattori Y, Nakaya H, Endou M, et al. Vascular effects of carvedilol, a new beta-adrenoceptor antagonist with vasodilating properties, in isolated canine coronary artery. J Cardiovasc Pharmacol 1989 Apr; 13: 572-9
8. Kawada T, Ishibashi T, Nakazawa M, et al. Adrenoceptor-blocking activity and cardiohemodynamic effects of carvedilol in animals. J Cardiovasc Pharmacol 1990 Jul; 16: 147-53
9. Abshagen U. A new molecule with vasodilating and β-adrenoceptor blocking properties. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S23-32
10. Nichols AJ, Sulpizio AC, Ashton DJ, et al. In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol, Pharmacology 1989; 39: 327-36
11. Sponer G, Bartsch W, Strein K, et al. Pharmacological profile of carvedilol as a β-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol 1987 Mar; 9: 317-27
12. Ruffolo Jr RR, Gellai M, Hieble JP, et al. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990; 38 Suppl, 2: S82-8
13. Bristow MR, Larrabee P, Müller-Beckmann B, et al. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig 1992; 70 Suppl. 1: S105-13
14. 2α- and noradrenaline-induced contraction of human hand veins in vivo. Clin Investig 1992; 70 Suppl. 1: S13-9
15. Seki N, Nagao T, Komori K, et al. Alpha and beta adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein. J Pharmacol Exp Ther 1988 Sep; 246: 1116-22
16. Ruffolo Jr RR, Sauermelch CF, Willette RN. Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation. Eur J Clin Pharmacol 1990; 38 Suppl. 2: S112-4
17. Bartsch W, Sponer G, Strein K, et al. Pharmacological characteristics of the stereoisomers of carvedilol, Eur J Clin Pharmacol 1990; 38 Suppl. 2: S104-7
18. Kuwahara M, Misu Y. Stereoselective antagonism by carvedilol against isoproterenol-induced facilitation of norepinephrine release in guinea-pig pulmonary arteries. Pharmacometrics 1989 Oct; 38: 199-202
19. Tomlinson B, Cronin CJ, Graham BR, et al. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S69-75
20. von Mollendorff E, Abshagen U, Akpan W, et al. Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clin Pharmacol Ther 1986 Jun; 39: 677-82
21. Cubeddu LX, Fuenmayor N, Varin F, et al. Clinical pharmacology of carvedilol in normal volunteers. Clin Pharmacol Ther 1987 Jan; 41: 31-44
22. Tomlinson B, Bompart F, Graham BR, et al. Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine. Drugs 1988; 36 Suppl, 6: 37-47
23. 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. Clin Pharmacol Ther 1994 Mar; 55: 329-37
24. Louis WJ, McNeil JJ, Workman BS, et al. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S89-93
25. Sundberg S, Tiihonen K, Gordin A. Vasodilatory effects of carvedilol and pindolol. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S76-80
26. Dupont AG, Van der Niepen P, Taeymans Y, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics. and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S130-6
27. Eggertsen R, Sivertsson R, Andrén L, et al. Haemodynamic effects of carvedilol, a new beta-adrenoceptor blocker and precapillary vasodilator in essential hypertension. J Hypertens 1984 Oct; 2: 529-34
28. Leonetti G, Sempieri L, Cuspidi C, et al. Resting and postexercise hemodynamic effects of carvedilol, a β-adrenergic blocker and precapillary vasodilator in hypertensive patients. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S94-6
29. Omvik P, Lund-Johansen P. Acute haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. Eur Heart J 1991 Jun; 12: 736-40
30. Heber ME, Brigden GS, Caruana MP, et al. Carvedilol for systemic hypertension. Am J Cardiol 1987 Feb 15; 59: 400-5
31. McPhillips JJ, Schwemer GT, Scott DI, et al. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs 1988; 36 Suppl. 6: 82-91
32. Loefsjoegaard-Nilsson E, Atmer B, Gunolf M, et al. Effects of carvedilol during exercise. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S108-13
33. Ajima H, Ota N, Igarashi S, et al. Phase I study of carvedilol (DQ-2466), a new β-blocker (the 1st report). The study in single oral administration [in Japanese]. Rinsho Yakuri 1990 Jun; 21: 391-400
34. Lund-Johansen P, Omvik P. Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. Eur Heart J 1992 Feb; 13: 281-6
35. Wendt T, van der Does R, Schrader R, et al. Acute hemodynamic effects of the vasodilating and beta-blocking agent carvedilol in comparison to propranolol. J Cardiovasc Pharmacol 1987; 10 Suppl. 1: S147-50
36. Schramm MS, Marks ML, Olsen SL, et al. Chronic beta-blocker therapy with carvedilol increases parasympathetic drive in heart failure [abstract no. 0545]. Circulation 1993 Oct; 88 (4): I-104
37. Bristow MR, Olson S, Gilbert EM, et al. β-blockade with carvedilol selectively lowers cardiac adrenergic drive in the failing human heart [abstract]. J Am Coll Cardiol 1992 Mar 1; 19 Suppl. A: 146
38. Doughty RN, Whalley GA, Sharpe DN. Improved ventricular contractility with carvedilol treatment of ischaemic heart failure [abstract]. Aust N Z J Med 1995 Oct; 25: 618
39. Quaife RA, Gilbert EM, Olsen SL, et al. Carvedilol improves left ventricular systolic but not diastolic function in heart failure [abstract no. 0548]. Circulation 1993 Oct; 88 (4): 104
40. Metra M, Nodari S, Raccagni D, et al. Chronic carvedilol therapy improves left ventricular systolic function but not filing rate in patients with idiopathic dilated cardiomyopathy [abstract]. Eur Heart J 1995 Aug; 16 Suppl.: 181
41. Raftery EB. The preventative effects of vasodilating beta-blockers in cardiovascular disease. Eur Heart J 1996 Apr; 17 Suppl. B: 30-8
42. Doughty RN, Whalley GA, Gamble G, et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997 April; 29 (5): 1060-6
43. Eichstaedt H, Schroeder RJ, Auffermann W, et al. Regression of left ventricular hypertrophy. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S55-61
44. Why HJF, Richardson PJ. Effect of carvedilol on left ventricular function and mass in hypertension. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S50-4
45. Schroeder R-J, Cordes M, Danne O, et al. Left ventricular hypertrophy regression and cardiac function under antihypertensive therapy: a comparison of a vasodilating beta-adrenoceptor blocker and an ACE-inhibitor. Perfusion 1994 Jun; 7: 210-8
46. James IM, Yogendran L, McLaughlin K, et al. Blood pressure lowering and cerebral blood flow: a comparison of the effects of carvedilol and propranolol on the cerebral circulation in hypertensive patients. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S40-3
47. Kuriyama Y, Nakamura M, Kyougoku I, et al. Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension. Eur J Clin Pharmacol 1990 May; 38 Suppl.: S120-1
48. Sievert H, Frey G, Schrader R, et al. Influence of carvedilol and propranolol on coronary blood flow. Eur J Clin Pharmacol 1990 May; 38 Suppl. 2: S122-4
49. Christopher TA, Lopez BL, Yue T-L, et al. Carvedilol, a new beta-adrenoreceptor blocker, vasodilator and free-radical scavenger, exerts an anti-shock and endothelial protective effect in rat splanchnic ischemia and reperfusion. J Pharmacol Exp Ther 1995 Apr; 273: 64-71
50. Brunvand H, Foyland L, Hexeberg E, et al. Carvediolol reduces infarct size and improves post-ischaemic functional recovery by protecting against both ischaemic and reperfusion injury [abstract]. Eur Heart J 1995 Aug; 16 Suppl.: 338
51. Feuerstein GZ, Ruffolo Jr RR. Comparison of the ability of two vasodilating β-blockers, carvedilol and celiprolol, to reduce infarct size in a pig model of acute myocardial infarction. Pharmacol Commun 1994 Sep; 5 (1): 57-63
52. Ruffolo Jr RR, Bril A, Feuerstein GZ. Cardioprotective potential of carvedilol. Cardiology 1993; 82 Suppl. 3: 24-8
53. Smith III EF, Griswold DE, Hillegass LM, et al. Cardioprotective effects of the vasodilator/beta-adrenoceptor blocker. carvedilol, in two models of myocardial infarction in the rat. Pharmacology 1992 Jun; 44: 297-305
54. Bril A, Slivjak M, DiMartino MJ, et al. Cardioprotective effects of carvedilol, a novel beta-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovasc Res 1992 May; 26: 518-25
55. Feuerstein GZ, Hamburger SA, Smith III EF, et al. Myocardial protection with carvedilol. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S138-41
56. Feuerstein GZ, Yue T-L, Cheng H-Y, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens 1993 Jun; II Suppl. 4: S41-48
57. Hoher M, Friedrich M, Sommer T, et al. Effects of carvedilol on left ventricular function and arrhythmias during repeated short-time myocardial ischemia in experimental pigs [in German]. Z Kardiol 1989; 78 Suppl. 3: 7-15
58. Bril A, Tomasi V, Laville M-P. Antiarrhythmic effects of carvedilol in rat isolated heart subjected to regional ischemia and reperfusion. Pharmacol Commun 1995; 5 (4): 291-300
59. Hashimoto K, Haruno A, Matsuzaki T. Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness? Cardiovasc Drugs Ther 1991 Aug; 5: 805-18
60. Hansen O, Johansson BW, Nisson-Ehle P, et al. Effects of carvedilol on the metabolic, hemodynamic, and electrocardiographic responses to increased plasma epinephrine in normal subjects. J Cardiovasc Pharmacol 1994 Dec; 24: 853-9
61. Cotter MA, Cameron NE. Neuroprotective effects of carvedilol in diabetic rats: prevention of defective peripheral nerve perfusion and conduction velocity. Naunyn Schmiedebergs Arch Pharmacol 1995 Jun; 351: 630-5
62. Lysko PG, Lysko KA, Webb CL, et al. Neuroprotective effects of carvedilol, a new antihypertensive, at the N-methyl-D-aspartate receptor. Neurosci Lett 1992 Dec 14; 148: 34-8
63. Yue T-L, Gu J-L, Lysko PG, et al. Antioxidant activity of a β-adrenoceptor antagonist, carazolol: comparison with propranolol and carvedilol. Pharmacol Commun 1995; 7 (1): 11-9
64. + channel modulator and glutamate transport inhibitor. Neurosci Lett 1994 Apr 25; 171: 77-80
65. Maxwell SRJ. Prospects for the use of antioxidant therapies. Drugs 1995; 49 (3): 345-61
66. Hockenbery DM, Olivai ZN, Yin X-M, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993 Oct 22; 75: 241-51
67. Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med 1992; 43: 219-25
68. Ambrosio G, Santoro G, Tritto I, et al. Effects of ischemia and reperfusion on cardiac tolerance to oxidative stress. Am J Physiol 1992; 262: H23-30
69. Hearse DJ. Prospects for antioxidant therapy in cardiovascular medicine. Am J Med 1991 Sep 30; 91 Suppl. 3C: 118S-21S
70. Flaherty JT, Myocardial injury mediated by oxygen free radicals. Am J Med 1991 Sep 30; 91 Suppl. 3C: 79S-85S
71. Entman ML, Michael L, Rossen RD, et al. Inflammation in the course of early myocardial ischemia. FASEB J 1991; 5: 2529-37
72. Downey JM. Free radicals and their involvement during long-term myocardial ischemia and reperfusion. Annu Rev Physiol 1990; 52: 487-504
73. Weglicki WB, Mak IT, Simic MG. Mechanisms of cardiovascular drugs as antioxidants. J Mol Cell Cardiol 1990; 22: 1199-208
74. Bolli R, Patel BS, Jeroudi MO, et al. Iron-mediated radical reactions upon reperfusion contribute to myocardial 'stunning'. Am J Physiol 1990; 259: H1901-11
75. Yue TL, McKenna PJ, Lysko PG, et al. Carvedilol, a new antihypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992 Dec; 97: 209-16
76. Yue TL, McKenna PJ, Ruffolo Jr RR, et al. Carvedilol, a new β-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol 1992 Apr 22; 214: 277-80
77. Yue T-L, Wang X, Gu J-L, et al. Carvedilol, a new vasodilating beta-adrenoceptor blocker, inhibits oxidation of low-density lipoproteins by vascular smooth muscle cells and prevents leukocyte adhesion to smooth muscle cells. J Pharmacol Exp Ther 1995 Jun; 273: 1442-9
78. Yue T-L, Liu T, Feuerstein G. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992; 1 (1): 27-35
79. Inamura T, Sato J, Mishimura H, et al. The effect of carvedilol on athersclerosis [abstract]. Atherosclerosis 1995 Jun; 115 Suppl.: S126
80. Yue T-L, Wang X, Gu J-L, Carvedilol prevents low-density lipoprotein (LDL)-enhanced monocyle adhesion to endothelial cells by inhibition of LDL oxidation. Eur J Pharmacol 1995 Dec 29; 294: 585-91
81. Lopez BL, Christopher TA, Yue T-L, et al. Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology 1995 Sep; 51: 165-73
82. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992 Oct; 263: 92-8
83. Yue TL, McKenna PJ, Gu JL, et al. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension 1993 Dec; 22: 922-8
84. Maggi E, Marchesi E, Covini D, et al. Protective effects of carvedilol, a vasodilating β-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996 Apr; 27: 532-8
85. Feuerstein R, Yue TL. A potent antioxidant, SB209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology 1994 Jun; 48: 385-91
86. Dupont AG. Carvedilol and the kidney. Clin Investig 1992; 70 (2) Suppl.: S127-31
87. Schlueter WA, Batlle DC, Renal effects of antihypertensive drugs. Drugs 1989; 37: 900-25
88. Leeman M, Vereerstraeten P. Uytdenhoef M. Systemic and renal hemodynamic responses to carvedilol and metoprolol in hypertensive renal transplant patients J Cardiovasc Pharmacol 1993 Nov; 22: 706-10
89. Tomita K, Marumo F. Effect of long-term carvedilol therapy on renal function in essential hypertension. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S97-S101
90. Sung C-P, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993 Feb; 21: 221-7
91. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 1993 Jul 1; 90: 6189-93
92. Patel MK, Chan P, Betteridge LJ. Inhibition of human vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol. J Cardiovasc Pharmacol 1995 Apr; 25: 652-7
93. Douglas SA, Vickery-Clark LM, Louden C, et al. Acute pretreatment with carvedilol is sufficient for inhibition of neointima formation following rat carotid artery balloon angioplasty. Pharmacol Commun 1994 Sep; 5(1): 65-72
94. Metsärinne KP, Saijonmaa O, Fyhrquist F. Carvedilol decreases release of endothelin-1 in vitro [abstract]. Eur Heart J 1995 Aug: 16 Suppl.: 489
95. 1 and β-adrenergic blockade affect plasma endothelin concentrations. Am J Hypertens 1996 Aug; 9: 819-22
96. Krum H, Gu A, Wilshire-Clement M, et al. Changes in plasma endothelin-1 levels reflect clinical response to β-blockade in chronic heart failure. Am Heart J 1996 Feb; 131: 337-41
97. Stienen U, Meyer-Sabellek W. Hemodynamic and metabolic effects of carvedilol: a meta-analysis approach. Clin Investig 1992; 70 (2) Suppl.: S65-72
98. Agrawal B, Stienen U. Long-term effect of carvedilol on lipids and blood glucose: a metaanalysis approach [abstract]. Can J Cardiol 1995 Jun; 11 Suppl. D: 62D
99. Seguchi H, Nakamura H, Aosaki N, et al. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects. Eur J Clin Pharmacol 1990 May; 38 Suppl. 2: S139-42
100. Cosenzi A, Sacerdote A, Bocin E, et al. Carvedilol reduces free fatty acids during exercise in young volunteers [abstract no. F4], Am J Hypertens 1995 Apr; 8: 129A
101. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996 Apr; 14: 489-94
102. Hauf-Zachariou U, Widmann L, Ztilsdorf B. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993; 45 (2): 95-100
103. Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994 May; 26: 335-46
104. Ruffolo Jr RR, Boyle DA, Venuti RP, et al. Preclinical and clinical pharmacology of carvedilol. J Hum Hypertens 1993 Feb; 7 Suppl. 1: S2-S15
105. von-Mollendorff E, Reiff K, Neugebauer G. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol 1987; 33: 511-3
106. Morgan T, Anderson A, Cripps J, et al. Pharmacokinetics of carvedilol in older and younger patients. J Hum Hypertens 1990 Dec; 4: 709-15
107. Neugebauer G, Akpan W, Kaufmann B, et al. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol 1990; 38 Suppl. 2: S108-11
108. Varin F, Cubeddu LX, Powell JR. Liquid chromatographic assay and disposition of carvedilol in healthy volunteers. J Pharm Sci 1986 Dec; 75 (12): 1195-7
109. Neugebauer G, Neubert P. Metabolism of carvedilol in man. Eur J Drug Metab Pharmacokinet 1991 Oct-Dec; 16: 257-60
110. Fujimaki M. Oxidation of R(+)- and S(-)-carvedilol by rat liver microsomes. Evidence for stereoselective oxidation and characterization of the cytochrome P450 isozymes involved. Drug Metab Dispos 1994 Sep-Oct; 22: 700-8
111. Deetjen A, Heidland A, Pangerl A, et al. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients. Clin Nephrol 1995 Jan; 43: 47-52
112. Kramer BK, Ress KM, Erley CM, et al. Pharmacokinetic and blood pressure effects of carvedilol in patients with chronic renal failure. Eur J Clin Pharmacol 1992 Jul; 43: 85-8
113. Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. J Cardiovasc Pharmacol 1992; 19 Suppl 1:S142-6
114. Tenero DM, Boyle DA, McSurdy-Freed JE, et al. Pharmacokinetics of carvedilol and its enantiomers in patients with renal insufficiency [abstract]. Pharmacotherapy 1995 May-Jun; 15: 393-4
115. Masumura H, Miki S, Kaifu Y, et al. Pharmacokinetics and efficacy of carvedilol in hypertensive patients with chronic renal failure and hemodialysis patients. J Cardiovasc Pharmacol 1992; 19 Suppl. 1:S102-7
116. Miki S, Masumura H, Kaifu Y, et al. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. J Cardiovasc Pharmacol 1991; 18 Suppl. 4: 62-8
117. Ogihara T, Ikeda M, Goto Y, et al. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension. J Cardiovasc Pharmacol 1987; 10 Suppl. 11: S108-12
118. Ogihara T, Goto Y, Yoshinaga K. et al. Dose-effect relationship of carvedilol in essential hypertension. An open study. Drugs 1988; 36 Suppl. 6: 75-81
119. van der Does R, Widmann L, Überbacher HJ, et al. Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide. Eur J Clin Pharmacol 1990; 38 Suppl. 2: S147-52
120. Cervantes Escarcega JL, Ruiz de Chávez A, Guadalajara Boo J, et al. Double-blind study of the efficacy and tolerability of carvedilol vs nifedipine S.R. in uncomplicated essential hypertension [in Spanish]. Invest Med Int 1992 Nov; 19: 142-7
121. Östergren J, Storstein L, Karlberg BE. Quality of life in hypertensive patients treated with either carvedilol or enalapril. Blood Press 1996 Jan; 5: 41-9
122. Ruilope LM, for the Carvedilol Study Group. Comparison of a new vasodilating beta blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. Am J Hypertens 1994 Feb; 7: 129-36
123. Weber K, Bohmeke T, van der Does R, et al. Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients. Cardiovasc Drugs Ther 1996 May; 10: 113-7
124. Langdon CG, Baxter GA, Young PH. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1991; 18 Suppl. 4: S51-6
125. Rittinghausen R. Response rate with respect to the blood pressure-lowering effect of the vasodilating and β-blocking agent carvedilol. Drugs 1988; 36 Suppl. 6: 92-101
126. Young PH, INT-CAR-07 (UK) Study Group. A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S82-5
127. Albergati F, Paternó E, Venuti RP, et al. Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S86-9
128. Seedat YK, Naiker I. Efficacy of carvedilol in hypertensive black patients: a pilot study. Curr Ther Res 1993 Dec; 54: 753-7
129. Agrawal B, Woft K, Berger A, et al. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996; 10: 551-5
130. Smekens P, Biemans M, Mattelaer P. Carvedilol in the management of hypertension in general practice: a prospective postmarketing surveillance study in Belgium. Acta Ther 1993; 19 (2): 213-21
131. Louis WJ, Krum H, Conway FL. A risk-benefit assessment of carvedilol in the treatment of cardiovascular disorders. Drug Saf 1994 Aug; 11: 86-93
132. van der Does R, Eherhardl R, Derr I, et al. Efficacy and safety of carvedilol in comparison with nifedipine sustained-release in chronic stable angina. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S122-7
133. Garnham SP, Gunawardena K, Haul-Zachariou U, et al. Carvedilol in chronic stable angina [abstract]. Clin Pharmacol Ther 1996 Feb; 59: 163
134. Senior R, Müller-Beckmann B, DasGupta P, et al. Effects of carvedilol on ventricular arrhythmias. J Cardiovasc Pharmacol 1992; 19 Suppl. 1: S117-21
135. Basu S, Senior R, van der Does R, et al. Carvedilol reduces adverse cardiac events following acute myocardial infarction [abstract]. Circulation 1995 Oct 15; 92 Suppl. 1: 1-20
136. Senior R, Basu S, Lahiri A. Carvedilol prevents remodelling and improves prognosis in patients with left ventricular dysfunction following acute myocardial infarction [abstract]. J Am Coll Cardiol 1996 Feb; 27 Suppl. A. 319A
137. Bril A, Feuerstein GZ, Ruffolo Jr RR. Carvedilol: a new paradigm for the treatment of congestive heart failure. Expert Opin Invest Drug 1996 Nov; 5: 1523-9
138. Kleber FX, Wensel R. Current guidelines for the treatment of congestive heart failure. Drugs 1996 Jan; 51: 89-98
139. Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-36
140. Feuerstein GZ, Ruffolo Jr RR. Carvedilol: preclinical profile and rationale for its use in hypertension, coronary syndromes, and congestive heart failure. Cardiovasc Rev Rep 1996 Oct; 17: 27-38
141. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94 (11): 2807-16
142. Cohn JN, Fowler MB, Bristow MA, et al. Effect of carvedilol in severe chronic heart failure [abstract]. J Am Coll Cardiol 1996 Feb; 27 Suppl. A: 169A
143. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996; 94: 2800-6
144. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 1996; 94: 2793-9
145. Packer M, Bristow MR, Cohn JN. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996 May 23; 334: 1349-55
146. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80
147. Krum H, Sackner-Bernstein JD, Goldsmith RL., et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995 Sep 15; 92: 1499-506
148. Metra M, Nardi M, Giubbini R. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994 Dec; 24: 1678-87
149. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995 May; 25: 1225-31
150. Bristow MR, Gilbert EM, Abraham WT, et al. Effect of carvedilol on LV function and mortality in diabetic versus nondiabetic patients with ischemic or nonischemic dilated cardiomyopathy [abstract no. 3879]. Circulation 1996 Oct 15; 94 (8) Suppl. 1: 1-664
151. Fowler MB, Gilbert EM, Cohn JN, et al. Effects of carvedilol on cardiovascular hospitalizations in patients with chronic heart failure [abstract]. J Am Coll Cardiol 1996 Feb; 27 Suppl. A: 169A
152. Carvedilol lowers costs in heart failure. SCRIP No. 2224, 18 Apr, 1997: 24
153. Gilbert EM, Shusterman N, Young S, et al. Carvedilol reduces the risk of clinical deterioration in chronic heart failure [abstract no. 3877]. Circulation 1996 Oct 15; 94 (8) Suppl. 1: 1-664
154. Packer M, Bristow MR, Shusterman N, et al. Maintenance of long-term survival benefit in CHF patients with carvedilol [abstract no. 3878]. Circulation 1996; 94 (8) Suppl. 1: 1-664
155. Moye LA, Abernethy D. Carvedilol in patients with chronic heart failure [letter]. N Engl J Med 1996 Oct 24; 335: 1318
156. von Olshausen K, Pop T, Berger J. Carvedilol in patients with chronic heart failure [letter]. N Engl J Med 1996 Oct 24: 335: 1318-9
157. Packer M, Cohn JN, Colucci WS. Carvedilol in patients with chronic heart failure [letter, reply]. N Engl J Med 1996 Oct 24; 335: 1319-20
158. Sackner-Bernstein J, Krum H, Goldsmith RL, et al. Should worsening heart failure early after initiation of beta-blocker therapy for chronic heart failure preclude long-term treatment ? [abstract]. Circulation 1995; 92 (8) Suppl. 1: 1-395
159. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997 Apr; 18 (4): 560-5
160. Bristow MR, Sharpe N, Colucci WS, et al. Duration of survival benefit in CHF patients treated with carvedilol [abstract no. 3876]. Circulation 1996 Oct 15; 94 (8) Suppl.: 1-664
161. Zehender M, Faber T, Schnabel P, et al. Benefits and hazards of carvedilol in unstable angina a double-blind, placebo-controlled, randomized study [abstract]. Circulation 1995 Oct 15; 92 Suppl. 1: 1-20
162. Desmet WJ, De Scheerder IK, Emanuelsson H, et al. Carvedilol in the prevention of restenosis after coronary angioplasty [abstract]. Circulation 1995 Oct 15; 92 Suppl. 1: 1-345
163. Schoors DF, De Wilde P, Block P. Effect of carvedilol on restenosis after coronary angioplasty: an observational study [abstract]. Acta Cardiol 1994; 49 (6): 528-9
164. Cauchic P, Vanden Abeele C, Biemans M, et al. A prospective postmarketing surveillance study of carvedilol in the management of hypertension in general practice [abstract]. J Hypertens 1992 Jun; 10 Suppl. 4: 191
165. Krum H, Conway EL, Broadbear JH, et al. Postural hypotension in elderly patients given carvedilol. BMJ 1994 Sep 24; 309: 775-6
166. Boehringer Mannheim GmbH. Carvedilol prescribing information. Federal Republic of Germany, 1991
167. Juttmann JR, de Vries Rubles P, Venuti RP. Safely of the coadministration of carvedilol and nifedipine sustained-release in the treatment of essential hypertension. J Cardiovasc Pharmacol 1992; 19 Suppl. 1:S134-7
168. de Mey C, Brendel E, Enterling D. Carvedilol increases the systemic bioavailability of oral digoxin. Br J Clin Pharmacol 1990; 29: 486-90
169. Wermeling DP, Field CJ, Smith DA, et al. Effects of long-term oral carvedilol on the steady-stale pharmacokinetics of oral digoxin in patients with mild to moderate hypertension. Pharmacotherapy 1994 Sep-Oct; 14: 600-6
170. Harder S, Brei R, Caspary S, et al. Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon. Eur J Clin Pharmacol 1993; 44: 583-6
171. Rudorf JE, Ehmer B. Pharmacokinetic and pharmacodynamic interactions of combined acute administration of carvedilol and hydrochlorothiazide in hypertensive volunteers. Drugs 1988; 36 Suppl. 6: 113-7
172. Boehringer Mannheim UK (Pharmaceuticals) Limited. Eucardic (carvedilol). Beta-blockade refined. Product monograph; July 1994
173. World Health Organization. Hypertension control: report of a WHO expert committee. Geneva: World Health Organization, 1996
174. WHO/ISH Guidelines Committee. 1993 guidelines for the management of mild hypertension: memorandum from a WHO/ ISH meeting. Hypertension 1993; 11: 905-18
175. Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC-V). Arch Intern Med 1993; 153: 154-83
176. Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert comittee on hypertension control. J Hypertens 1996 Aug; 14: 929-33
177. Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 1995 Nov 8; 274: 1462-7
178. van Zwieten PA. Changing insights in the drug treatment of congestive heart failure. Expert Opin Invest Drug 1995; 4 (11): 1045-56
179. Hampton JR. Beta-blockers in heart failure - the evidence from clinical trials. Eur Heart J 1996; 17 Suppl. B: 17-20